-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
6 views
enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, ENGN maintains a cash runway into 2027, supporting ongoing development without major liquidity concerns in the near term. While regulatory discussions are encouraging, the investment thesis hinges on positive LEGEND trial results, making this a high-risk, high-reward scenario.
